Traders should monitor for topline data from the LOTUS trial in Q2 2026, which will be a critical catalyst. The sharp revenue decline and widening loss underscore high dependency on clinical success, increasing risk ahead of data readout.
Price Chart
Executive Summary
Avalo Therapeutics reported its 2025 financial results, highlighting a net loss of $78.3 million amid increased R&D spending for its Phase 2 LOTUS trial of abdakibart (AVTX-009) in hidradenitis suppurativa. The company ended 2025 with $98.3 million in cash, projecting a runway into 2028, with topline data from the trial expected in Q2 2026. Revenue declined sharply from $441K to $59K year-over-year.
Key Financial Metrics
Key Facts
- Net loss widened to $78.3 million in 2025 from $35.1 million in 2024
- Revenue dropped from $441,000 in 2024 to $59,000 in 2025
- R&D expenses nearly doubled to $50.1 million, driven by the LOTUS trial
- Cash, cash equivalents, and short-term investments totaled $98.3 million as of December 31, 2025
- Company expects funding runway into 2028
- Topline data from Phase 2 LOTUS trial expected in Q2 2026
Financial Impact
Revenue declined by 86.6%, net loss more than doubled, and operating expenses increased significantly despite one-time 2024 R&D charge
Risk Factors
- Clinical trial failure could severely impact valuation given minimal revenue and high R&D dependency
- Dilution risk if additional funding is required before or after 2028
- Recent insider selling ($412K in 30 days) may signal lack of confidence
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260233 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $20.75 $16.69 | ▼ −19.57% | ▼ −17.61% | $14.99 (−27.76%) |
Aug 17, 2026 6w ago | Institutional Cluster | $19.95 $16.07 | ▼ −19.45% | ▼ −17.47% | $14.99 (−24.86%) |
Aug 6, 2026 8w ago | 8-K | $18.70 $19.00 | ▲ +1.60% | ▲ +1.00% | $14.99 (−19.84%) |
Jun 16, 2026 15w ago | 8-K | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 16, 2026 15w ago | Press Release | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 8, 2026 16w ago | 8-K | $12.90 $19.25 | ▲ +49.22% | ▲ +47.78% | $14.99 (+16.20%) |
May 13, 2026 20w ago | 8-K | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 13, 2026 20w ago | Press Release | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 6, 2026 21w ago | Press Release | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
May 6, 2026 21w ago | Insider Cluster | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access